A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

  • Lung Cancer
Trial Status:


This trial runs in
  • A Coruña
  • Aberdeen
  • Basel
  • Göttingen
  • Hlavní město Praha
  • Madrid
  • Warszawa
Trial Identifier:

NCT03092739 MO29978

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT03092739 , MO29978 Trial Identifier
      PD-L1 Immunocytochemistry (ICC), PD-L1 Immunohistochemistry (IHC) Treatments
      Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Condition
      Official Title

      A Non-Interventional Multinational Study to Assess PD-L1 Expression in Cytological Versus Histological Non-Small Cell or Small Cell Lung Cancer Specimens

      Eligibility Criteria

      All Gender
      No Healthy Volunteers
      Inclusion Criteria
      • Samples must have been collected in a manner that is compliant with local ethics committee guidance
      • Samples must originate from participants diagnosed with NSCLC or SCLC
      • Participants must have a pair of at least one cytological and one histological specimen that: Both originate from inside the thorax or from the same ex-thoracic site; Are confirmed to have been collected within a window no more than 6 weeks apart from each other; and are in compliance with the protocol defined sample requirements for histological and cytological specimens
      Exclusion Criteria
      • Immune checkpoint inhibitor therapy from 4 weeks prior to collection of the first tumor sample until collection of the second matched sample

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now